{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:21:36Z","timestamp":1792718496253,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.intimp.2022.109545","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:55:46Z","timestamp":1670547346000},"page":"109545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Combination therapy in inflammatory bowel disease: Current evidence and perspectives"],"prefix":"10.1016","volume":"114","author":[{"given":"Cong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.109545_b0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2022.109545_b0010","doi-asserted-by":"crossref","unstructured":"Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239-254.","DOI":"10.1093\/ecco-jcc\/jjv213"},{"issue":"1","key":"10.1016\/j.intimp.2022.109545_b0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11938-017-0130-6","article-title":"Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature","volume":"15","author":"Darr","year":"2017","journal-title":"Curr Treat Options Gastroenterol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109545_b0020","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109545_b0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2022.109545_b0030","doi-asserted-by":"crossref","unstructured":"Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2016;14(2):251-258 e251-252.","DOI":"10.1016\/j.cgh.2015.10.029"},{"issue":"7","key":"10.1016\/j.intimp.2022.109545_b0035","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.intimp.2022.109545_b0040","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.intimp.2022.109545_b0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2022.109545_b0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: drug levels and disease activity","volume":"11","author":"Ben-Horin","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109545_b0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.intimp.2022.109545_b0060","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2022.109545_b0065","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109545_b0070","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109545_b0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/apt.13102","article-title":"Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis","volume":"41","author":"Christophorou","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2022.109545_b0080","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/jgh.12517","article-title":"Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis","volume":"29","author":"Hayes","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109545_b0085","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.dld.2019.05.001","article-title":"Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent","volume":"51","author":"Polakovicova","year":"2019","journal-title":"Dig. Liver Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.109545_b0090","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1080\/00365521.2020.1792543","article-title":"Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?","volume":"55","author":"Arieira","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109545_b0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG Clinical Guideline: Management of Crohn's Disease in Adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109545_b0100","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.intimp.2022.109545_b0105","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.intimp.2022.109545_b0110","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2014.07.027","article-title":"Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease","volume":"13","author":"Drobne","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109545_b0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2022.109545_b0120","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.crohns.2014.07.003","article-title":"Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J. Crohns Colitis"},{"issue":"12","key":"10.1016\/j.intimp.2022.109545_b0125","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2014-307126","article-title":"Systematic review: Monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD","volume":"63","author":"Dulai","year":"2014","journal-title":"Gut"},{"issue":"9613","key":"10.1016\/j.intimp.2022.109545_b0130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2022.109545_b0135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective","volume":"10","author":"Matsumoto","year":"2016","journal-title":"Randomized Trial. J Crohns Colitis."},{"key":"10.1016\/j.intimp.2022.109545_b0140","doi-asserted-by":"crossref","unstructured":"Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. Clin Gastroenterol Hepatol. 2015;13(13):2233-2240 e2231-2232; quiz e2177-2238.","DOI":"10.1016\/j.cgh.2015.06.034"},{"issue":"3","key":"10.1016\/j.intimp.2022.109545_b0145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.intimp.2022.109545_b0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.intimp.2022.109545_b0155","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cgh.2015.02.017","article-title":"Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease","volume":"13","author":"Osterman","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109545_b0160","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.109545_b0165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT Registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109545_b0170","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109545_b0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.intimp.2022.109545_b0180","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.109545_b0185","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cgh.2020.06.071","article-title":"No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis","volume":"19","author":"Yzet","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109545_b0190","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","article-title":"Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab","volume":"62","author":"Allegretti","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2022.109545_b0195","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management","volume":"11","author":"Harbord","year":"2017","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"10.1016\/j.intimp.2022.109545_b0200","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ecco-jcc\/jjx179","article-title":"New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents: Cyclosporine Plus Vedolizumab","volume":"12","author":"Szanto","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"3","key":"10.1016\/j.intimp.2022.109545_b0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cgh.2018.04.060","article-title":"Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease","volume":"17","author":"Christensen","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109545_b0210","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cgh.2018.08.081","article-title":"Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis","volume":"17","author":"Pellet","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109545_b0215","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/apt.15616","article-title":"Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis","volume":"51","author":"Ollech","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2022.109545_b0220","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ibd\/izx110","article-title":"Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series","volume":"24","author":"Buer","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.intimp.2022.109545_b0225","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2020.02.017","article-title":"Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center","volume":"19","author":"Kwapisz","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109545_b0230","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J. Dig. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2022.109545_b0235","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2022.109545_b0240","article-title":"Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease","author":"Privitera","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"10.1016\/j.intimp.2022.109545_b0245","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40272-020-00396-1","article-title":"Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature","volume":"22","author":"Olbjorn","year":"2020","journal-title":"Paediatr. Drugs"},{"issue":"12","key":"10.1016\/j.intimp.2022.109545_b0250","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/17512433.2018.1548277","article-title":"Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis","volume":"11","author":"Stiff","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109545_b0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/03007995.2019.1673581","article-title":"Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors","volume":"36","author":"Pugliese","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"10.1016\/j.intimp.2022.109545_b0260","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2022.109545_b0265","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692201030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692201030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:49:23Z","timestamp":1761587363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692201030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":53,"alternative-id":["S156757692201030X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109545","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy in inflammatory bowel disease: Current evidence and perspectives","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109545"}}